This is an old revision of this page, as edited by BogBot (talk | contribs) at 22:25, 2 September 2011 (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 22:25, 2 September 2011 by BogBot (talk | contribs) (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.207.679  |
| Chemical and physical data | |
| Formula | C9H11ClN2O |
| Molar mass | 198.649 g·mol |
| 3D model (JSmol) | |
SMILES
| |
| (verify) | |
Tebanicline (Ebanicline, ABT-594) is a drug developed by Abbott, which acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes. It was developed as a less toxic analogue of the potent frog-derived compound epibatidine, which is some 200x stronger than morphine as an analgesic but produces extremely dangerous toxic side effects. Like epibatidine, tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound.
Tebanicline got as far as Phase II trials in humans, but was dropped from further development due to unacceptable incidence of gastrointestinal side effects. However further research in this area is ongoing, and it is expected that development of new neural nicotinic acetylcholine receptor agonists will be likely to lead to novel analgesics suitable for use in humans within the next few years.
References
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 14983978, please use {{cite journal}} with
|pmid=14983978instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9417028, please use {{cite journal}} with
|pmid=9417028instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9484491, please use {{cite journal}} with
|pmid=9484491instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9580626, please use {{cite journal}} with
|pmid=9580626instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9580627, please use {{cite journal}} with
|pmid=9580627instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9617748, please use {{cite journal}} with
|pmid=9617748instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 10779668, please use {{cite journal}} with
|pmid=10779668instead. - Sorbera LA, Revel L, Leeson PA, Castaner J. ABT-594. Drugs Future 2001; 26: 927-934).
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15713428, please use {{cite journal}} with
|pmid=15713428instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11772288, please use {{cite journal}} with
|pmid=11772288instead. - Meyer MD. Neuronal Nicotinic Acetylcholine Receptors as a Target for the Treatment of Neuropathic Pain. Drug Development Research. 2006; 67: 355-359.
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15745813, please use {{cite journal}} with
|pmid=15745813instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16412637, please use {{cite journal}} with
|pmid=16412637instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17585748, please use {{cite journal}} with
|pmid=17585748instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18088559, please use {{cite journal}} with
|pmid=18088559instead. - Lloyd GK, Williams M. Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets. Journal of Pharmacology and Experimental Therapeutics. 2000; 292:461-467.
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16185161, please use {{cite journal}} with
|pmid=16185161instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17662959, please use {{cite journal}} with
|pmid=17662959instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18508600, please use {{cite journal}} with
|pmid=18508600instead.
| Acetylcholine receptor modulators | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||
 | This analgesic-related article is a stub. You can help Misplaced Pages by expanding it. |